# OZEM (Roundhill GLP-1 & Weight Loss ETF)

Roundhill · Thematic ETFs · data as of Sep 11, 2026

OZEM holds 25 stocks, and 74% of its weight is outside the S&P 500.

## Key facts

- OZEM, already in the S&P 500: 26.0%, as of Sep 11, 2026.
- OZEM, active share vs the S&P 500: 97.8%, as of Sep 11, 2026.
- OZEM, top ten holdings: 65.0%, as of Sep 11, 2026.
- OZEM, total return, 1 year: +21.1%, as of Sep 11, 2026.
- OZEM, net assets: $58m (the issuer own daily fund list, as of Sep 11, 2026).
- OZEM, expense ratio: 0.59% (485BPOS XBRL, Apr 30, 2026).

## OZEM over each window to Sep 11, 2026

| Window | Total return | S&P 500 | Gap to S&P 500 | Gap to Nasdaq-100 |
| --- | --- | --- | --- | --- |
| 3 months | +1.9% | +3.3% | −1.4 pts | +2.7 pts |
| 6 months | −0.6% | +16.0% | −16.6 pts | −21.3 pts |
| 1 year | +21.1% | +17.5% | +3.6 pts | −1.9 pts |
| Since launch | +24.4% | +47.7% | −23.3 pts | −34.3 pts |

## Every published field

| Field | Value | Source |
| --- | --- | --- |
| Theme | Healthcare innovation and GLP-1 | ETFIQ, editorial |
| Launched | May 21, 2024 | ETFIQ |
| Already in the S&P 500, by weight | 26.0% | ETFIQ |
| Active share vs the S&P 500 | 97.8% | ETFIQ |
| Already in the Nasdaq-100, by weight | 6.2% | ETFIQ |
| Active share vs the Nasdaq-100 | 98.5% | ETFIQ |
| Top ten holdings weight | 65.0% | ETFIQ |
| Holdings | 25 | ETFIQ |
| Holdings published for | Sep 11, 2026 | the issuer’s daily file |
| Top holdings | Eli Lilly & Co 12.2%, Novo Nordisk A/S 12.1%, Pfizer Inc 7.6%, CSPC Pharmaceutical Group Ltd 6.9%, Viking Therapeutics Inc 5.0%, Hanmi Pharm Co Ltd 4.9%, Chugai Pharmaceutical Co Ltd 4.2%, Amgen Inc 4.2%, Kailera Therapeutics Inc 4.1%, Zealand Pharma A/S 4.0% | ETFIQ |
| Net assets | $58m | the issuer own daily fund list, as of Sep 11, 2026 |
| Below its all-time high | −15.9% | ETFIQ |
| Expense ratio | 0.59% | 485BPOS XBRL, Apr 30, 2026 |
| Fee for the part that differs from the S&P 500, active expense ratio | 0.60% | ETFIQ |

## Questions

### How much of OZEM is in S&P 500 companies?

By its holdings published by its issuer for Sep 11, 2026, 26% of OZEM by weight is stocks the S&P 500 already holds. Its active share against the index is 98%, so that share is the part doing something different.

### What does OZEM hold?

25 positions as published by its issuer for Sep 11, 2026, with the top ten at 65% of the fund. The largest are Eli Lilly & Co at 12.2%, Novo Nordisk A/S at 12.1%, Pfizer Inc at 7.6%.

### Has OZEM beaten the S&P 500?

Over the year to Sep 11, 2026 OZEM returned +21.1% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 3.6 points.

### What does OZEM cost?

The prospectus expense ratio is 0.59% a year. Because 98% of the fund differs from the S&P 500, the fee on that differing part works out at 0.60%.


## Cite this page

ETFIQ, OZEM, data as of Sep 11, 2026. https://etfiq.com/funds/ozem
Free to use with attribution; the underlying files are at https://etfiq.com/data/.

HTML: https://etfiq.com/funds/ozem  ·  JSON: https://etfiq.com/funds/ozem.json